These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 9591585)

  • 21. Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent.
    Deshpande SV; DeNardo SJ; Kukis DL; Moi MK; McCall MJ; DeNardo GL; Meares CF
    J Nucl Med; 1990 Apr; 31(4):473-9. PubMed ID: 2324823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biodistribution and dosimetry of pretargeted monoclonal antibody 2D12.5 and Y-Janus-DOTA in BALB/c mice with KHJJ mouse adenocarcinoma.
    Lubic SP; Goodwin DA; Meares CF; Song C; Osen M; Hays M
    J Nucl Med; 2001 Apr; 42(4):670-8. PubMed ID: 11337558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
    J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.
    Nayak TK; Regino CA; Wong KJ; Milenic DE; Garmestani K; Baidoo KE; Szajek LP; Brechbiel MW
    Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1368-76. PubMed ID: 20155263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody.
    Vallera DA; Brechbiel MW; Burns LJ; Panoskaltsis-Mortari A; Dusenbery KE; Clohisy DR; Vitetta ES
    Clin Cancer Res; 2005 Nov; 11(21):7920-8. PubMed ID: 16278417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives.
    Béhé M; Becker W; Gotthardt M; Angerstein C; Behr TM
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1140-6. PubMed ID: 12768330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts.
    Safavy A; Khazaeli MB; Safavy K; Mayo MS; Buchsbaum DJ
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):2994s-3000s. PubMed ID: 10541333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.
    Nikula TK; McDevitt MR; Finn RD; Wu C; Kozak RW; Garmestani K; Brechbiel MW; Curcio MJ; Pippin CG; Tiffany-Jones L; Geerlings MW; Apostolidis C; Molinet R; Geerlings MW; Gansow OA; Scheinberg DA
    J Nucl Med; 1999 Jan; 40(1):166-76. PubMed ID: 9935073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.
    van Schaijk FG; Oosterwijk E; Soede AC; Oyen WJ; McBride WJ; Griffiths GL; Goldenberg DM; Corstens FH; Boerman OC
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts.
    Lee FT; Rigopoulos A; Hall C; Clarke K; Cody SH; Smyth FE; Liu Z; Brechbiel MW; Hanai N; Nice EC; Catimel B; Burgess AW; Welt S; Ritter G; Old LJ; Scott AM
    Cancer Res; 2001 Jun; 61(11):4474-82. PubMed ID: 11389078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse.
    Sato N; Saga T; Sakahara H; Yao Z; Nakamoto Y; Zhang M; Kuroki M; Matsuoka Y; Iida Y; Konishi J
    J Nucl Med; 1999 Apr; 40(4):685-92. PubMed ID: 10210230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting strategies for cancer radiotherapy.
    Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved in vivo stability and tumor targeting of bismuth-labeled antibody.
    Ruegg CL; Anderson-Berg WT; Brechbiel MW; Mirzadeh S; Gansow OA; Strand M
    Cancer Res; 1990 Jul; 50(14):4221-6. PubMed ID: 2364380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice.
    Adams GP; Shaller CC; Dadachova E; Simmons HH; Horak EM; Tesfaye A; Klein-Szanto AJ; Marks JD; Brechbiel MW; Weiner LM
    Cancer Res; 2004 Sep; 64(17):6200-6. PubMed ID: 15342405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study.
    Riva P; Franceschi G; Frattarelli M; Lazzari S; Riva N; Giuliani G; Casi M; Sarti G; Guiducci G; Giorgetti G; Gentile R; Santimaria M; Jermann E; Maeke HR
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3275s-3280s. PubMed ID: 10541375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
    van Schaijk FG; Oosterwijk E; Molkenboer-Kuenen JD; Soede AC; McBride BJ; Goldenberg DM; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2005 Mar; 46(3):495-501. PubMed ID: 15750164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice.
    Schneider DW; Heitner T; Alicke B; Light DR; McLean K; Satozawa N; Parry G; Yoo J; Lewis JS; Parry R
    J Nucl Med; 2009 Mar; 50(3):435-43. PubMed ID: 19223400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of 225actinium chelates: tissue distribution and radiotoxicity.
    Davis IA; Glowienka KA; Boll RA; Deal KA; Brechbiel MW; Stabin M; Bochsler PN; Mirzadeh S; Kennel SJ
    Nucl Med Biol; 1999 Jul; 26(5):581-9. PubMed ID: 10473198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
    Hens M; Vaidyanathan G; Zhao XG; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2010 Oct; 37(7):741-50. PubMed ID: 20870149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.